Tifcemalimab

Summary

Tifcemalimab (CHEMBL5095352) is a phase-3 clinical-stage antibody; indicated across 11 conditions including hodgkins lymphoma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 11 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095352
Name	Tifcemalimab
Type	Antibody
Max phase	3

Also known as: Icatolimab, JS004, TAB-004, Tifcemalimab, TIFCEMALIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Hodgkins lymphoma	3	MONDO:0004952	EFO:0000183
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
gastric adenocarcinoma	1	MONDO:0005036	EFO:0000503
lymphoma	1	MONDO:0005062	EFO:0000574
esophageal squamous cell carcinoma	1	MONDO:0005580	EFO:0005922
lung neoplasm	1	MONDO:0021117	MONDO:0008903
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575
nasopharyngeal carcinoma	1	MONDO:0015459	MONDO:0015459

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	3
PHASE1/PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06095583	PHASE3	RECRUITING	Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT05891080	PHASE2	NOT_YET_RECRUITING	Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
NCT06256237	PHASE2	RECRUITING	Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
NCT06370754	PHASE1/PHASE2	NOT_YET_RECRUITING	Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
NCT06648200	PHASE2	NOT_YET_RECRUITING	Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
NCT06690697	PHASE2	RECRUITING	Combination of Toripalimab and JS004 Therapy for ccRCC
NCT04929080	PHASE1/PHASE2	COMPLETED	The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC
NCT04477772	PHASE1	COMPLETED	A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China
NCT05427396	PHASE1	TERMINATED	A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
NCT06732258	PHASE1	WITHDRAWN	Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).